RxDoctor Payments Data

Sunday Irene, MD

Family Medicine · Bakersfield, CANPI 1154541019

Payments from drug & device makers

$746in general payments, 2019–2025

Across 34 payments — averaging $21.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$96
  • Shield Therapeutics Inc$74
  • Exact Sciences$70
  • Novo Nordisk$61
  • Gilead$49
  • Medtronic$46
  • plus $351 from 13 others

What the payments were for

  • Food & beverage$746100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$746 in reported general payments places this provider in the 70th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$1,875
Medicare patients
82
Services billed
206

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin174$158,309
OzempicSemaglutide149$136,195
JanuviaSitagliptin Phosphate101$104,458
RybelsusSemaglutide84$89,906
TradjentaLinagliptin92$73,770
FarxigaDapagliflozin Propanediol82$72,296
EliquisApixaban48$44,297
LinzessLinaclotide44$34,321
TrulicityDulaglutide20$18,567
Combivent RespimatIpratropium/Albuterol Sulfate38$17,843
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog25$14,895
Tresiba Flextouch U-100Insulin Degludec20$14,694
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$11,440
Lantus SolostarInsulin Glargine,hum.Rec.Anlog68$10,388
MyrbetriqMirabegron11$6,939

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$41$249,921304 claims
Novo NordiskOzempic, Rybelsus$61$226,101233 claims
MerckJanuvia$30$104,458101 claims
AstraZenecaFarxiga$17$72,29682 claims
AbbVieLinzess$96$34,32144 claims
Lilly USA, LLCTrulicity$23$18,56720 claims
GSKTrelegy Ellipta$42$11,44012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,533 family medicine providers in California.

Other family medicine in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →